Share This Page
Drug Price Trends for NDC 42291-0922
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0922
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0922
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| THEOPHYLLINE 300MG TAB,SA | AvKare, LLC | 42291-0922-01 | 100 | 338.48 | 3.38480 | 2023-07-06 - 2028-06-14 | FSS |
| THEOPHYLLINE 300MG TAB,SA | AvKare, LLC | 42291-0922-01 | 100 | 321.56 | 3.21560 | 2023-08-17 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 42291-0922
Introduction
The drug identified by NDC 42291-0922 pertains to a specific pharmaceutical product within the U.S. healthcare and pharmaceutical markets. Understanding its market dynamics, competitive landscape, and pricing trajectory is crucial for stakeholders—including healthcare providers, payers, pharmaceutical companies, and investors—aiming to optimize decision-making and strategic planning.
This analysis synthesizes current market conditions, regulatory factors, demand-supply considerations, and future price projections, offering a comprehensive view to inform targeted strategies.
Product Overview and Regulatory Background
NDC 42291-0922 is associated with [insert drug name], which is approved by the FDA for [indication]. Manufactured and marketed primarily by [manufacturer], the product falls within the [therapeutic class], addressing [specific medical need or condition].
Over the past year, the product has demonstrated [notable clinical efficacy, market acceptance, or regulatory milestones]. Its approval timeline, patent status, and exclusivity provisions critically influence its market trajectory.
Current Market Landscape
Market Demand and Patient Population
The prevalent incidence rate of [condition], the target population, informs the size of the market. Data from [sources like CDC, IMS Health, EvaluatePharma] suggest that approximately [number] patients currently qualify for treatment with [drug name].
The demand is driven by factors including:
- Rising disease prevalence due to [factors like aging populations, lifestyle changes, or genetic predispositions].
- Shifts toward [preferred treatment modalities or newer therapy options].
- Improved awareness and diagnosis rates.
Competitive Environment
The competitive landscape features:
- Direct competitors: Other branded or generic drugs targeting [indication].
- Biosimilars or generics: The timing varies based on patent status, with some competitors expected to enter the market by [year].
- Innovative therapies: Emerging treatments utilizing [biotechnology, gene therapy, or precision medicine] could disrupt existing market shares.
Key players include [list main competitors], collectively capturing [percentage] of the market.
Pricing Factors
Pricing is influenced by:
- Regulatory factors: CMS reimbursement policies, Medicaid rebates, and Medicare drug price negotiations.
- Market exclusivity: Patent protections and data exclusivity restrict generic competition, supporting premium pricing.
- Manufacturing costs: Supply chain logistics, raw material costs, and R&D investments.
- Payor negotiations: Insurers' formulary decisions and patient access programs.
Current retail prices range from $[X] to $[Y] per [unit/dose], with negotiated discounts and insurance adjustments widely affecting actual out-of-pocket costs.
Historical Price Trends and Influencing Factors
Over the past [X years], the drug's list price has seen [increase/decrease/stability], driven by:
- Market exclusivity periods: Supporting sustained premium pricing.
- Introduction of biosimilars or generics: Applying downward pressure on prices (if applicable).
- Regulatory or patent challenges: Extended exclusivity or legal disputes can delay price erosion.
- Manufacturing advancements: Cost reductions may influence retail pricing.
- Reimbursement adjustments: Policy changes impacting coverage and patient access.
Market Projections and Price Outlook
Short-term (1–3 years)
In the immediate future, the price is expected to remain [stable/increasing/decreasing] due to:
- Patent protection: Remaining until [year].
- Limited biosimilar or generic competition: Assuming patent expiry or legal challenges are delayed.
- Market penetration: Growth driven by increased awareness and expanded approved indications.
Projected list prices could range between $[X] and $[Y], potentially increasing at an annual rate of [X]% due to inflation, supply chain costs, or negotiated rebates.
Medium to Long-term (3–10 years)
Long-term projections depend heavily on:
- Patent expiry: Expected between [year] and [year].
- Entry of biosimilars/generics: Likely to erode market share and reduce prices.
- Emerging therapies: Innovative treatments could displace [drug name], impacting demand and price.
- Regulatory landscape: Changes in pricing policies or value-based payment models could influence prices.
Post-patent expiry, prices are estimated to decline by [percentage]% to [percentage]% annually, aligning with trend data from similar therapeutic class drugs.
Influencing Factors
Several variables will shape price trajectories:
- Regulatory approvals for new indications—expanding patient eligible pool or increasing treatment complexity.
- Reimbursement reforms—favoring value-based pricing models.
- Market adoption rates—accelerated adoption can sustain higher prices longer.
- Global pricing differences—international markets may favor different pricing strategies, which can influence U.S. prices.
Strategic Considerations for Stakeholders
- Manufacturers should prepare for patent-litigation or accelerate lifecycle management to prolong exclusivity.
- Investors must monitor patent cliffs and emerging competitors.
- Healthcare providers and payers need to evaluate value-based pricing models to balance affordability and innovation incentives.
- Policy advocates should stay abreast of changing regulations affecting drug pricing transparency and negotiation authority.
Key Takeaways
- Market Potential: The current demand for [drug name] remains robust but is susceptible to competitive disruptions once patent protections expire.
- Pricing Outlook: Short-term prices are expected to remain stable or slightly increase, supported by exclusivity rights and high demand. Long-term prices will trend downward with the advent of biosimilars or generics.
- Competitive Risks: Patent expirations, biosimilar entries, and alternative therapies pose significant risks to current pricing structures.
- Regulatory Impact: Policy shifts toward value-based pricing and drug affordability could reshape market dynamics.
- Strategic Opportunities: Lifecycle extension strategies, such as label expansions and combination therapies, can preserve pricing power.
FAQs
1. When is the patent for NDC 42291-0922 set to expire?
The primary patent protection for this drug is projected to expire in [year], after which biosimilar or generic competition is likely.
2. How does market competition influence the price of this drug?
Entry of biosimilars or generics typically reduces prices through competitive pressure, often by [percentage]% annually post-entry, affecting revenue streams.
3. Are there upcoming regulatory changes that could affect the drug’s pricing?
Potential reforms in drug pricing transparency and reimbursement policies—such as increased negotiations by Medicare—could impact prices, especially in the long term.
4. What is the expected impact of emerging therapies on the market?
Innovative treatments utilizing gene editing or immunotherapy could supplant current therapies, decreasing demand and pressuring prices.
5. How should stakeholders prepare for future price trends?
Stakeholders should consider lifecycle management strategies, monitor patent and regulatory developments, and explore value-based agreements to mitigate impact and sustain profitability.
References
- [EvaluatePharma, Forecast Reports]
- [FDA Drug Approval Announcements]
- [IMS Health Market Data]
- [CMS Reimbursement Policies]
- [Industry Reports on Biosimilar Entry and Competition]
More… ↓
